PPT-Access to Controlled Medicines

Willem Scholten PharmD MPA Team Leader Access to Controlled Medicines World Health Organization Geneva Switzerland TECHNICAL BRIEFING SEMINAR Geneva 29 October 2 November 2012 Overview. –. lessons from HIV. EPIP, 5 September 2017, Bordeaux. . Ellen ‘t Hoen, LLM. University Medical Centre Groningen, Global Health Unit. @. ellenthoen. www.medicineslawandpolicy.org. Brief history. Stops AIDS National Gathering . 1st November 2014. Aliénor Devali. ère. Health. Action International (HAI) Europe. This document arises from HAI Europe’s Operating Grant 2014, which has received funding from the . Willem Scholten, PharmD, MPA. Team Leader, Access to Controlled Medicines,. World Health Organization, Geneva, Switzerland. TECHNICAL BRIEFING SEMINAR . Geneva, 29 October – 2 November 2012. Overview. Gilles Forte. Policy. , Access and Use Team. Department for Essential . Medicines and Health Products. World Health Assembly Resolution 67.22 . Access . to essential medicines. Recognize . the importance of effective national medicines policies, and their . Gilles . Forte. Coordinator, Policy, Access and Use Team. Essential . Medicines . and . Health Products. . WHO . mandate . within the . International . Drug Control Conventions. 1961 . Single Convention on Narcotic Drugs (Article 3). WHO EMP and NVI Departments. Access to NCD essential medicines . on the global agenda. Access to chronic disease medicines is required for the fulfilment of MDG8. Governments, in collaboration with the private sector, should give greater priority to treating chronic diseases and improving the accessibility of medicines to treat them (MDG Report 2009). sustainably and equitably financed. Summary Discussion…1. What information needed to estimate cost program of medicines benefits. MBM . Ned to estimate the total economic cost of setting up a MBM program. Development. Esteban Burrone. Head of Policy. Medicines. Patent Pool. Collaboration to promote innovation and . aCCESS. TO MEDICINES. Innovation. and . Access. are two sides of the same coin and central to ensuring improvements in public health outcomes worldwide. Draft concept for a new World Bank-led multi-stakeholder initiative . August 2014, Andreas . Seiter. What is AIM 2030?. An initiative to maximize access to innovative medicines for priority diseases in low- and middle income countries (LMICs). Willem Scholten, PharmD, MPA. Team Leader, Access to Controlled Medicines,. World Health Organization, Geneva, Switzerland. TECHNICAL BRIEFING SEMINAR . Geneva, 29 October – 2 November 2012. Overview. Dr Cécile . Macé. . WHO EMP , Mr Arne-Petter . Sanne. WHO MND, . Mr . Ajuebor. Onyema WHO MND. NCD Programme Managers Seminar. 4 June 2014. Access to NCD essential medicines . on the global agenda. Case Management. George Jagoe . EVP, Access & Product Management, MMV. . . The access team at MMV is heavily focused on the needs of control today. 4. Achieving patient impact means addressing many hurdles to access. how . the pandemic has influenced the disease burden. Bengt . Jönsson. Professor emeritus, Stockholm School of Economics. Wednesday, 1 July 2020 – 16.30-19.00 CET (online event. ). Launch of the European Parliament  . Basic enquiry answering. September . 2016. Session aims. Increase awareness of the Medicines Information (MI) services. UK. Wales. Increase awareness of the questions to ask an enquirer. Have practical experience using some resources which will be...